Results 231 to 240 of about 222,357 (321)
Cuproplasia and cuproptosis, two sides of the coin
Abstract Copper is an essential micronutrient in the human body, mainly acting as a crucial cofactor required for a wide range of physiological processes across nearly all cell types. Recent advances revealed that tumor cells seize copper to fulfill their rapid proliferation, metastasis, immune evasion, and so on by reprogramming the copper regulatory ...
Kaizhong Lu+4 more
wiley +1 more source
A Radiologist's Guide to IDH-Wildtype Glioblastoma for Efficient Communication With Clinicians: Part I-Essential Information on Preoperative and Immediate Postoperative Imaging. [PDF]
Vollmuth P+5 more
europepmc +1 more source
Breaking barriers: Smart vaccine platforms for cancer immunomodulation
Abstract Despite significant advancements in cancer treatment, current therapies often fail to completely eradicate malignant cells. This shortfall underscores the urgent need to explore alternative approaches such as cancer vaccines. Leveraging the immune system's natural ability to target and kill cancer cells holds great therapeutic potential ...
Mohammad Mahmoudi Gomari+11 more
wiley +1 more source
Glioblastoma Cells Express and Secrete Alternatively Spliced Transcripts of Coagulation Factor X. [PDF]
Li X+17 more
europepmc +1 more source
Copper in cancer: friend or foe? Metabolism, dysregulation, and therapeutic opportunities
Abstract Copper, one of the essential nutrients for the human body, acts as an electron relay in multiple pathways due to its redox properties. Both deficiencies and excesses of copper lead to cellular fragility. Therefore, it can manifest pro‐ and anti‐cancer properties in tumors. Therefore, it is crucial to clarify the copper activity within the cell.
Dan Shan+13 more
wiley +1 more source
Post-operative spread of small cell glioblastoma to the subcutaneous tissue via craniotomy defect in a 9-year-old boy: An exceptionally rare case report and review of the literature. [PDF]
Zaresharifi N+3 more
europepmc +1 more source
Abstract Background Glioblastoma (GBM) is largely refractory to antibodies against programmed cell death 1 (anti‐PD‐1) therapy. Fully understanding the cellular heterogeneity and immune adaptations in response to anti‐PD‐1 therapy is necessary to design more effective immunotherapies for GBM.
Rongrong Zhao+11 more
wiley +1 more source